Minerva Neurosciences, INC. (NERV) — 10-Q Filings

10-Q Filings (6)

• Minerva Swings to $9.76M Loss, Secures $80M for Roluperidone Trial — Nov 5, 2025 Risk: high
  Minerva Neurosciences, Inc. (NERV) reported a significant net loss of $9.76 million for the nine months ended September 30, 2025, a stark contrast to the net in
• NERV's Losses Narrow Amid R&D Cuts, But Liquidity Concerns Mount — Aug 14, 2025 Risk: high
  Minerva Neurosciences, Inc. (NERV) reported a net loss of $3.26 million for the three months ended June 30, 2025, a significant improvement from the $8.23 milli
• Minerva Neurosciences Files Q1 2025 10-Q — May 13, 2025 Risk: medium
  Minerva Neurosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus is on the development of pharmaceutical preparation
• Minerva Neurosciences Files Q3 2024 10-Q — Nov 5, 2024 Risk: medium
  Minerva Neurosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company's financial statements reflect its ongoing operations in the ph
• Minerva Neurosciences Files Q2 2024 10-Q — Aug 6, 2024 Risk: medium
  Minerva Neurosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the six months ended
• Minerva Neurosciences Files 10-Q for Period Ending March 31, 2024 — May 1, 2024 Risk: medium
  Minerva Neurosciences, Inc. (NERV) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Minerva Neurosciences, Inc. filed a 10-Q report for the period e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX